Arthritis is a prevalent disease that causes joint inflammation in individuals of all ages. Its symptoms often include joint pain and stiffness, loss of mobility, and eventually, joint destruction.
Traditional arthritis treatments, such as pain management medication and joint replacement surgery, have their own limitations and risks. Newer approaches like bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP) are being studied as additional options for patients who want to explore joint preservation first.
BMAC is a cell-based therapy derived from the patient’s own bone marrow. It is a minimally invasive procedure used to support healing in the affected joint. PRP is a concentrated preparation from the patient’s own blood that contains growth factors intended to help reduce inflammation and support repair.
Early research suggests that BMAC and PRP may help reduce pain and improve joint function for some patients with arthritis. The evidence base is still developing, study designs and patient selection vary widely, and results differ between individuals, so published figures should be discussed with your surgeon rather than treated as an expected outcome.
For appropriately selected patients, BMAC and PRP offer some practical advantages compared with surgery. The approach is minimally invasive, so there are no surgical incisions, no scarring and no hospital stay. It is also autologous, meaning it uses the patient’s own cells, which minimizes the risk of rejection. The procedure cost is generally lower than surgery once hospitalization and physician fees are considered, though these injections are often not covered by insurance.
For patients who want to explore joint preservation before committing to replacement, these treatments are worth discussing. They are less invasive than surgery and aim to support the function of the affected joint. They are not a guaranteed alternative to surgery, and more research and clinical trials are needed to establish their long-term effect in patients with arthritis. The honest way to approach them is as one option within a broader plan, chosen after an evaluation rather than in place of one.
PRP is concentrated from your blood, while BMAC is concentrated from your bone marrow and contains a broader mix of cells. They are frequently used together because they contribute different biological components.
The combination pairs the cellular content of marrow concentrate with the growth factors found in platelet rich plasma. The intent is to support the joint environment more completely than either preparation does alone.
Patients with mild to moderate arthritis who want to delay joint replacement, and who still have workable joint space, are the usual candidates. An examination and a review of your imaging determine suitability.
Replacement reliably relieves pain in advanced arthritis but permanently removes the joint surface, while these injections aim to preserve your own anatomy in earlier disease. They address different stages rather than competing directly.
The research is promising but still developing, and results vary between patients. They are best considered one option within a broader plan discussed candidly with your surgeon.
Reviewed by Dr. Richard Scheinberg, MD, a board-certified orthopedic surgeon in Santa Barbara with 40 years of surgical experience.
